Pfizer will manufacture Gilead's emergency coronavirus drug remdesivir to scale up its supply
Gilead Sciences' potential coronavirus treatment is getting a supply chain boost.
Pfizer has entered a multi-year agreement with Gilead to manufacture its antiviral drug remdesivir, which has been FDA approved for emergency use to fight coronavirus, the pharmaceutical company announced Friday. The partnership is intended to ramp up production of the intravenous drug.
While no drug has been approved for the treatment of coronavirus, remdesivir has been approved for emergency use. A study showed the drug, which was developed as a potential Ebola treatment, significantly reduced the risk of death in severely sick COVID-19 patients. At the beginning of July, the Trump administration bought up all the remdesivir Gilead was set to produce in July, August, and September. Pfizer will start ramping up that production even further through contract manufacturing services at its McPherson, Kansas, facility.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Concerns still remain over the price of remdesivir. At $520 per dose, it could cost a patient $3,000 over a typical coronavirus treatment. State attorneys general have sought to enforce a federal patent law that would force Gilead to increase the supply of the drug and lower its price; the partnership with Pfizer will hopefully provide Gilead the bandwidth to do that.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
Political cartoons for October 26Cartoons Sunday’s editorial cartoons include Young Republicans group chat, Louvre robbery, and more
-
Why Britain is struggling to stop the ransomware cyberattacksThe Explainer New business models have greatly lowered barriers to entry for criminal hackers
-
Greene’s rebellion: a Maga hardliner turns against TrumpIn the Spotlight The Georgia congresswoman’s independent streak has ‘not gone unnoticed’ by the president
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
